Maximum-likelihood phylogenetic tree of gag sequences. The tree comprises nucleotide sequences from each individual along with the MRKAd5, HXB2 and CON_B04 sequences and is rooted with sequences from the only subject not infected with a subtype B virus (CRF02-AG). Sequences from placebo recipients are in blue, whereas sequences from vaccine recipients are in red. Sequences from individuals with two or more founder variants are highlighted in yellow. The sequences from related viruses found in two individuals are labeled with the two subjects' identification numbers. The scale bar at the bottom refers to the degree of the sequence mismatch.
homogeneous populations found in acute or early HIV-1 infection. We found no evidence of phylogenetic clustering on the basis of vaccine or placebo status (Fig. 1) . We also performed phylogenetic analyses with all volunteer-derived env nucleotide sequences (n = 459) along with 243 circulating sequences isolated since 2000 in Canada, Peru and the US 3 (Supplementary Fig. 1) , choosing env to maximize the phylogenetic signal and the inclusion of contemporary circulating sequences. Sequences from vaccine and placebo recipients were interspersed among contemporary circulating sequences irrespective of vaccine or placebo status, and there was limited geographic clustering. We identified a possible linkage between two vaccine recipients, and we confirmed it with later specimens.
Whole-gene and protein sieve analyses
Measures of viral sequence diversity and divergence from the MRKAd5 insert sequences showed higher values for gag, pol and nef nucleotide sequences from vaccinees than from placebo recipients, yet these differences were generally not significant (data not shown), indicating that the volunteer sequences were not globally distinguishable by treatment assignment. Only in gag did the mean population diversity differ significantly: 0.0026 among vaccinees versus 0.0014 among placebo recipients (P = 0.022). Protein divergence from the MRKAd5 vaccine insert sequences also tended to be higher among vaccinees (data not shown).
Next, we compared private and phylogenetically informative mutations: private mutations are found in only one sequence in an All  67  1  35  23  10  52  3  13  32  27  9  40  28   Vaccine  40  0  18  17  5  30  1  9  18  18  4  22  18   Placebo  27  1  17  6  5  22  2  4  14  9  5  18  10   This includes only subjects with infections identified before 1 January 2008. Ab, antibody; CAN, Canada; NA, not available. intraindividual set, whereas phylogenetically informative mutations occur in at least two sequences. There was no distinction between vaccine and placebo groups, except for private mutations in Gag (data not shown). The proportion of private mutations (number of private mutations divided by the number of sequences for each individual) was higher among vaccinees compared to placebo recipients (mean 0.331 versus 0.178; P = 0.026), implying that private mutations, that is, those found at the tips of the phylogenetic trees and that are not yet fixed or not fixed because they are deleterious, were more frequent among vaccinees.
Predicted CTL epitope sieve analysis
The peptide HLA-binding predictor NetMHC 4 predicted on all consensus founder variants; 2,061 potential epitopes were predicted in Gag, Pol and Nef for distance comparisons with MRKAd5. The number of predicted epitopes per individual did not differ between vaccine and placebo recipients (median 29 versus 31; P = 0.9). Overall, mean epitopic distances to MRKAd5 were significantly larger for vaccine than for placebo recipients (0.061 versus 0.049; P = 0.007), indicating that, within probable epitopes, founder sequences were more divergent from the vaccine among vaccinees ( Fig. 2a) . On a protein level, only Gag-specific epitopic distances were significantly larger for vaccine than for placebo recipients (mean 0.076 versus 0.034; P < 0.0001) ( Fig. 2b-d) .
We evaluated the presence of known HLA class I polymorphisms in predicted epitopes from volunteers' sequences mismatched compared to MRKAd5, using as reference HLA-associated sites described previously 5 . Among all volunteers' predicted epitopes, 642 NetMHC epitopes differed from the MRKAd5, and 449 of these (70%) showed mutations typical of known CTL-mediated pressure in subtype B sequences.
As MRKAd5 expressed gag, pol and nef, a vaccine-mediated impact on founder sequences could be confined to these proteins and not other HIV-1 proteins. We therefore conducted the above analysis using the full proteomes of HIV-1 HXB2 and the subtype B 2004 consensus sequence (CON_B04) 3 as references. HXB2 is a typical 'ancestral' strain and corresponds to one of the vaccine inserts (consisting of HIV-1 strains CAM-1, HXB2 and JRFL), and CON_B04 is contemporary to the viruses the volunteers were infected with. We expected distances to be higher against MRKAd5 and HXB2 than against CON_B04. Distance comparisons comprised 3,235 NetMHC-predicted epitopes with HXB2 and 3,318 with CON_B04. For HXB2-derived epitopes for Gag-Pol-Nef, epitopic distances were larger among vaccinees than among placebo recipients (mean 0.069 versus 0.060; P = 0.02) ( Fig. 3a) . In contrast, there was no distinction if epitopes from Env-Rev-Tat-Vif-Vpr-Vpu were considered (mean 0.126 versus 0.118; P = 0.42) (Fig. 3b ). The largest difference was seen in Gag: 0.085 among vaccine versus 0.045 among placebo recipients (P < 0.0001). Also showing that the reference did not bias our results, mean epitopic distances to CON_B04 were larger among vaccinees in the vaccine insert proteins but not in the remainder of the proteome: 0.053 versus 0.044 (P = 0.04) for Gag-Pol-Nef and 0.097 versus 0.098 (P = 0.97) for Env-Rev-Tat-Vif-Vpr-Vpu ( Fig. 3c,d) . Again, the largest distance between vaccine and placebo against CON_B04 resided in Gag: 0.073 versus 0.031 (P < 0.0001).
We obtained comparable results using Epipred for epitope predictions; the main difference was that the signal was stronger in Nef than in Gag (Supplementary Results and Supplementary Fig. 2 ).
Oligomer sieve analysis
The above sieve analyses compared only predicted CTL epitopes; any founder sequence peptide with mutations that precluded its identification as an epitope was excluded. Therefore, we calculated the 'epitope mismatch distance' , which measures the percentage of founder sequences with mismatches when compared to NetMHC-derived epitopes in MRKAd5. We found greater percentages of mismatches among vaccinees than among placebo recipients (P = 0.01) ( Supplementary Fig. 3 ). Mirroring the epitope distance results, only Gag-specific mismatch distances were significantly larger for vaccine compared to placebo recipients (P < 0.0001) ( Supplementary Fig. 3b ). With HXB2 as reference, the distances calculated based on Gag-Pol-Nef tended to be higher among vaccinees (P = 0.06), whereas there was no difference for distances from proteins not in MRKAd5 ( Supplementary Fig. 3e,f) .
Sieve analysis of distances and stratification of the cohort
A sieve effect might be strongest in vaccinees who adhered to the vaccine regimen and had measurable T cell responses before infection. Hence, we repeated sieve analyses for adherent vaccinees with a week-8 interferon-γ (IFN-γ) ELISPOT response, but distances were not greater in the restricted population (data not shown). There was also no evidence that the interval from last vaccination to sequence sampling (range 22-549 d), or the number of immunizations before infection (range 1-3) biased the assessment of the sieve effect ( Supplementary Fig. 4 ).
Amino acid signature site sieve analysis
At each amino acid site, we compared the residues in founder HIV-1 sequences to the residue in MRKAd5 and measured the rate of amino acid mismatches to identify signature sites distinguishing between vaccine and placebo recipients. We identified ten signature sites with a q value < 0.20: four in Gag, two in Pol and four in Nef. We found no signature sites in the control protein Env (Fig. 4) .
Signature site Gag84 showed the greatest distinction between vaccine and placebo recipients (q = 0.012): it is encompassed by several known CTL epitopes, including the well-characterized HLA-A*02 epitope SLYNTVATL (amino acids 77-85; italicized T is the site showing the distinction between vaccine and placebo recipients). Thirty-six of 64 subjects had an HLA class I allele restricting epitopes that spanned Gag84 (ref. 6) . The signature at Gag84 was more pronounced among individuals with an HLA allele matching an ' A-list' epitope (epitopes fulfilling criteria intended to ensuring reliable description of the optimal length epitope and correct assignment of the restricting HLA class I alleles) 7 (79%:17% mismatch vaccine:placebo compared to 80%:46% mismatch in the 28 subjects without an A-list restricting allele), supporting that vaccine-induced T cell pressure led to the high rate of mismatch among vaccine recipient founder sequences. Additional signature sites included Gag211 located in the HLA-A*2501 epitope ETINEEAAEW (amino acids 203-212) (q = 0.09). The consensus residue Glu211, found in 93% of circulating sequences, was found in all sequences from placebo recipients and in 33 of 39 vaccinees. However, five of the latter six vaccinees had an allele restricting a potential epitope covering position 211. Gag84 was the only significant signature site after stringent Holm-Bonferroni correction (P = 0.01), owing to the high frequency of HLA-A*02 among volunteers and the multiplicity of epitopes encompassing that site. The corollary is that we had limited power to detect amino acid mutations associated with rare HLA alleles in our cohort. As CD8 + T cell epitopes are nonamers, we performed a similar antigen-scanning analysis to identify nonamers with significantly different distance distributions in vaccinees compared to placebo recipients. Fourteen nonamers had greater distances among vaccinees: ten in Gag (two encompassed signature sites described above) and four in the epitope-rich region Nef121-132 (Supplementary Table 2 ). Notably, some of the identified k-mers (oligomers of any (k) length) mapped to protein regions with no predicted epitopes.
CTL responses in vaccinees before infection
To relate the above data to detectable CTL responses, we conducted IFN-γ ELISPOT assays 4 weeks after the second vaccination but before HIV-1 infection with peripheral blood mononuclear cells from 27 of the 39 vaccinees with sequence data and peptides corresponding to the immunogen ( Fig. 5) . Of the 27, only 21 had at least one response to Gag, Pol or Nef. CTL responses elicited by the vaccine generally corresponded to predicted epitopes, but few responses were detected, thus precluding our ability to detect a sieve effect using only the epitope recognition data. (Epitope predictions based on Epipred are shown in Supplementary Fig. 5 ).
DISCUSSION
Ideally, our analyses would have focused on CTL responses induced by the vaccine and detected in vaccine recipients before infection. However, the paucity of CTL responses identified, and only in a subset of vaccine recipients (21 individuals), precluded statistically powered analyses for reasons unknown. To evaluate more subjects than the immune reactivity data allowed, our sequence analyses included both the vaccine and placebo groups. Because the clinical trial was randomized and doubleblinded, and the analysis restricted to infections diagnosed during the blinded period, the observed sequence differences between vaccine versus placebo are causally attributable to vaccine assignment. Our results showed that the MRKAd5 vaccine had an impact on breakthrough viral populations: viruses infecting vaccinees were more likely to encode epitopes that differed from those present in the vaccine. Moreover, the difference between vaccine and placebo recipients was confined to the segments of the virus included in the vaccine, that is, Gag, Pol and Nef, whereas other proteins did not differ by treatment assignment.
As the vaccine lacked clinical efficacy, it is remarkable that it left a genetic imprint on the founder viral strains. A sieve effect for CTLbased vaccines can be understood either as the exclusion of specific HIV-1 variants (the ones that are the most similar to the vaccine inserts) from establishing a sustained infection as a result of killing by vaccine-elicited CTL or as the 'diversion' of the founder variants, driven to accumulate more CTL-mediated mutations, accumulate them faster or both, a process that requires escape followed by selective outgrowth of the escape mutant during acute infection. It is difficult to distinguish these hypotheses with the current data, and both processes could act concomitantly. We found no direct evidence of a selective exclusion at transmission, as the vaccinees were more likely to become infected than placebo recipients 1 , single or multiple founder variants were equally likely to be found in both groups, and phylogenetic analyses showed no clustering of founder viruses according to vaccine/placebo status. The fact that the sieve effect was seen only in predicted epitopes and only in proteins that were components of the vaccine suggests the possibility of T cell-mediated selection occurring after infection. Additional factors (albeit weaker ones) concur with the hypothesis of T cell-mediated selection after infection: phylogenetic analyses of gag showed that genetic distances calculated between volunteers' sequences (or between volunteers' sequences and the vaccine sequence) tended to be higher among vaccinees, whereas genetic distances calculated from the most recent common ancestor were not, and the proportion of private mutations was higher among gag nucleotide sequences from vaccine recipients. These two related observations suggest that the variation corresponds to recent events during infection that have not been fixed (as opposed to more basal effects that could have reflected founder events with more divergent strains among vaccinees). Such evidence support that CTL responses primed by the vaccine could have elicited anamnestic CTL responses, that is, the responses could have occurred sooner or more frequently during breakthrough infection than in placebo recipients, leading to accelerated CTL escape. The possibility of early CTL escape after HIV-1 vaccination has been reported in an HLA-B27 + vaccine recipient 8 . The mutation R264G was found in the Gag KK10 epitope and caused viral escape in the third year of infection, a much shorter time frame than typical for a KK10 escape [9] [10] [11] , but much later than the time span evaluated here. Another group recently compared the fate of macaques vaccinated with either a single Gag epitope or a full Gag insert 12 . They reported fast escape mutations and no control of viremia for macaques vaccinated with the single epitope construct as opposed to no escape mutations for that same epitope and control of viremia in macaques immunized with full-length Gag. This suggests that a vaccine that does not elicit a broad enough response could provoke rapid escape mutations, a pattern that is reminiscent of the STEP immunizations that elicited only narrow CTL responses.
Counterbalancing findings in favor of post-infection selection, and arguing in favor of restriction of specific variants from establishing infection (despite a overall higher infection rate in vaccinees), is our failure to detect simultaneously both the unmutated and escape forms of epitopes in vaccinees' sequences. Our finding of a sieve effect on breakthrough viruses provides impetus for designing new vaccine inserts: we postulate that vaccine pressure should be elicited in a controlled manner for a vaccine to be beneficial; that is, the vaccine should trigger mutations in regions of the virus known to be associated with viral control and should avoid prematurely creating a cycle of escape variants that could act as immunodominant decoys 13 . Therefore, we propose that 'cornering' the virus to taking on potentially debilitated forms should be a goal for new designs of CTL-based vaccines.
To our knowledge, the results presented here are the first to demonstrate an impact of vaccination on viruses establishing HIV-1 infection, and Gag was the principally correlated vaccine target. The differences in genetic distances across HIV-1 genes reflected their intrinsic variability, and differences based on reference strains were also expected, with shorter distances to the contemporary CON_B04 than to the ancestral HXB2 sequence. The fact that pol is subjected to the strongest purifying selection (selection to maintain the amino acid sequence) renders the detection of differences more difficult and may explain the lack of significance in pol. Imprinting on gag was most robustly supported in both our phylogenetic and sieve analyses; yet, on the basis of Epipred-derived epitopes, the statistically significant differences seemed to be mostly driven by differences in nef. Given that the epitope prediction tools we used were trained on partially different data sets and assumptions, they rely on potentially different features of epitope-MHC binding; therefore we may expect nonredundant information and possibly discrepancies between prediction methods. It is recognized that the predictors are not extremely accurate because our catalog of known epitopes is limited, and multiple operating pathways intersect between the degradation of a protein and the presentation of an epitope 14 . Numerous studies have shown varying performances of predictive algorithms depending on data sets and alleles, yet there has been no critical assessment of the various methods, and, as such, no consensus on an ideal epitope prediction method 15 . Notably, Pol (e,f). For each protein, the top graph (a,c,e) represents the location of predicted epitopes based on NetMHC in vaccine and placebo groups (light and medium gray columns, respectively), amino acid signature sites (dashed lines) and signature k-mers (horizontal bars). The bottom graph (b,d,f) corresponds to IFN-γ ELISPOT responses detected in 21 vaccine recipients before infection. Fifteen-amino-acid peptides overlapping by 11 amino acids were used to assess responses. The region covered by each responsive peptide is shown as the box width, whereas the number of subjects reacting with that peptide is given by the box height.
the sieve analyses based on k-mers, which are free of epitope predictions, corroborated the analyses based on predicted epitopes.
The hallmarks of CTL pressure were identified over broader epitopic regions than estimated by the CTL responses measured before infection, suggesting that vaccine-elicited T cells may be sufficient to affect genetic features of breakthrough viruses without detection of responses by conventional IFN-γ ELISPOT assays (N.F. and M.J.M., unpublished data). It would seem, however, that the vaccine-elicited responses lacked sufficient immunogenicity, were not targeting protective epitopes or were weak and thus easily evaded. Although the selective forces we detected were not sufficient to prevent infection or reduce viral loads, they do provide a new benchmark to evaluate the impact of forthcoming vaccines. The selective impact on founding viruses may have resulted from CTLs below current levels of detection or potentially from other selective forces such as targeting by CD4 + T cells or the innate immune system. It remains to be established what the impact of anamnestic responses is on the kinetics of emergence of escape mutants, and whether vaccine-mediated selection had a prolonged effect on viral sequence evolution or an effect on viral replication capacity. Assessing whether vaccine-mediated polymorphisms in founding viruses affected viral fitness is also worth exploration, as a fitness-impaired virus could translate into a reduction in viral loads and attenuation of disease progression.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Accession codes. HIV-1 viral genome sequences, along with associated subject-specific information, have been deposited in GenBank with accession codes JF320002_JF320643.
Note: Supplementary information is available on the Nature Medicine website.
ONLINE METHODS

Study subjects.
Participants underwent a thorough written informed consent process. The protocol was approved by the ethics review committee of each of the 34 sites in North America, the Caribbean, South America and Australia, and the study was undertaken in conformance with applicable local and country requirements.
HIV-1 near full-length genome sequencing. PCR products corresponded to single amplifiable viral genomes derived from plasma collected at HIV-1 diagnosis. GenBank accession numbers are provided under Methods in the main text.
Our strategy was to obtain five to ten NFLG sequences per specimen, depending on intrahost sequence variation assessments: if five or more phylogenetically informative sites were found in the first five NFLGs, then five additional NFLGs were sequenced. Phylogenetically informative sites correspond to mutations that are found in at least two sequences (http://indra.mullins.microbiol.washington. edu/cgi-bin/InSites/index.cgi).
Phylogenetic analyses.
Maximum-likelihood phylogenetic trees were reconstructed by estimating the GTR-I-G nucleotide substitution model and included sequences for all volunteers as well as MRKAd5, HXB2 and CON_B04 sequences. Pairwise diversity and tree-based divergence measures were calculated from the most recent common ancestor, MRKAd5, HXB2 and CON_B04 sequences.
Cytotoxic T lymphocyte epitope prediction. Known HIV-1 epitopes were included, and potential CTL epitopes were predicted with NetMHC 4 (http:// www.cbs.dtu.dk/services/NetMHC/) and Epipred 16 (http://atom.research. microsoft.com/bio/epipred.aspx/). NetMHC predicts binding of peptides to four-digit HLA alleles; we accepted known epitopes reported at the Los Alamos National Laboratory HIV database and variant epitopes that had identical HXB2 coordinates and were strong or weak binders. Epipred identifies known and potential HIV-1 CTL epitope motifs using two-digit HLA information. HLAspecific epitopes were predicted in all HIV-1 proteins derived from the volunteers' sequences and in the corresponding consensus founder sequences, on the basis of each individual's HLA genotype. Sequences from three volunteers were excluded (non-B subtype virus; nonmale volunteer; no HLA genotype). Epitopes were also identified in MRKAd5, HXB2 and CON_B04 sequences.
Sieve analyses. We performed both 'global' sieve analyses, which are based on summary measures of distances between volunteer sequences and a reference sequence, and 'local' sieve analyses, which identify signature positions and peptides between the vaccine and placebo group.
Whole-protein tree-based sieve analysis. Tree-based distances were calculated with an HIV-specific substitution model of protein evolution (HIV-10) 17 . For each individual, the average of the distances between the MRKAd5 HIV-1 sequence and each volunteer sequence was computed, and comparisons between the vaccine and placebo groups were done with a Wilcoxon/Mann-Whitney test.
Global sieve effects restricted to CTL epitopes from founder variants. Two T cell epitope-based distance measures were used: the 'CTL epitope' and 'k-mer' distances. For the subset of predicted epitopes that were shared in the volunteers' and reference sequence (with at most two amino acid differences), we computed pairwise distances using the HIV-10 model. For each subject, the CTL epitope distance was the average of the different epitope-specific pairwise distances.
K-mer distances are based on epitopes in the reference sequence and allow inclusion of mutated forms of the epitopes in the volunteers' sequences that would not be recognized as epitopes. Using NetMHC predictions, we defined the distance as the estimated percentage of mismatched epitopes, that is the number of k-mers in the reference sequence that had mismatches against the corresponding peptide in the founder sequences.
Global sieve effects restricted to CTL epitopes in all individual sequences. Parallel to above but based on all volunteer-derived sequences.
Signature positions in founder variants. For each site in Gag, Pol and Nef, we compared the rate of amino acid mismatch to the MRKAd5 insert between the vaccine group and placebo group. The same analysis was done for Env with HXB2 as reference. We used a previously published t statistic numerator-type statistic and permutation procedure 18 to compute an unadjusted P value for each position. To account for multiple tests, we applied the Holm-Bonferroni multiplicity adjustment procedure with Tarone's 19 modification to improve power, and also estimated q values.
Signature positions in all individual sequences. For each position, we estimated the probability of a mismatch between an individual sequence and the reference sequence (either MRKAd5 or HXB2) for the vaccine and placebo groups. If a position is a signature position, the parameter estimated by this difference will be significantly different from zero. Unadjusted P values were computed using the nonparametric bootstrap (robust with different numbers of sequences per subject). The analyses were performed on all positions for which at least four subjects had a nonconsensus amino acid in at least one of their sequences. Adjusted P values and q values were computed as in the section about signature positions in founder variants.
Signature k-mer peptides based on all individual sequences.
For each k-mer peptide in the MRKAd5 and HXB2 reference sequences, we compared the distribution of similarity scores for all of the individual sequences between the vaccine and placebo groups. For each sequence, we computed a similarity score to the reference k-mer by selecting the closest similarity score across all k-mers in that sequence. The estimated means were computed using generalized estimating equations to fit restricted-moment models (marginal mean models), using a Gaussian model with exchangeable correlation structure.
Additional methods. Detailed methodology is described in the Supplementary Methods.
